Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

66.44EUR
18 May 2018
Change (% chg)

€0.32 (+0.48%)
Prev Close
€66.12
Open
€66.22
Day's High
€66.89
Day's Low
€65.77
Volume
4,760,278
Avg. Vol
2,884,702
52-wk High
€89.43
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 30.95 32.75
EPS (TTM): 3.70 -- --
ROI: 5.69 14.84 14.38
ROE: 8.50 16.34 16.07

CVC puts $9 billion Recordati bid on hold as political uncertainty weighs -sources

LONDON/MILAN Buyout fund CVC Capital Partners held talks with Italian drugmaker Recordati over a possible 8 billion euro ($9.4 billion) takeover, but has put the deal on hold due to concerns about the hefty price tag and political uncertainty, three sources familiar with the matter said.

17 May 2018

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

01 May 2018

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

01 May 2018

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

01 May 2018

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

01 May 2018

BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* REG-SANOFI: FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

30 Apr 2018

UPDATE 2-Sanofi sees new acquisitions and drugs reviving growth

* Shares down 1.5 percent (Adds quotes from CEO, analyst comment, shares)

27 Apr 2018

Sanofi Q1 hit by exchange rates, diabetes, growth not seen before second half

PARIS, April 27 French drugmaker Sanofi posted sluggish first-quarter profits on Friday, hurt by exchange rate effects and lower sales at its struggling diabetes and cardiovascular unit, and hinted at another difficult quarter ahead.

27 Apr 2018

BRIEF-FDA Accepts For Review Sanofi's Supplemental Biologics License Application

* FDA ACCEPTS FOR REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR 0.5 ML DOSE OF FLUZONE® QUADRIVALENT (INFLUENZA VACCINE) IN CHILDREN 6-35 MONTHS OF AGE

25 Apr 2018

Boehringer's operating income up 20.7 percent on Sanofi deal

FRANKFURT, April 25 Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine.

25 Apr 2018

Earnings vs. Estimates